Hormone Therapy - malecare.org

Degarelix Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonists Plus Antiandrogen Flare Protection For Men With Advanced Prostate Cancer *

There are a number of different flavors of hormone therapy (ADT) used to treat advanced prostate cancer. However, they could be summed up and put into two different categories. 1- The use of luteinizing hormone-releasing hormone (LHRH) agonist therapy (drugs like Lupron and Zoladex) along with short term antiandrogen (AA) flare protection 2- Degarelix, a [...]

By Malecare|2020-02-04T11:51:33-05:00December 4th, 2014|ADT, Advanced Prostate Cancer, Androgan Receptor Inhibitor, degarelix, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Bone Complications Among Prostate Cancer Survivors Having Prolonged Hormone Therapy (ADT)

Androgen deprivation therapy (ADT) and bone complications are the two near universals for men with advanced prostate cancer. A long-term follow up of fifteen (15) years after diagnosis of a population-based cohort of prostate cancer survivors proved to be very informative. The Prostate Cancer Outcomes Study, which enrolled 3533 men diagnosed with prostate cancer between [...]

By Malecare|2020-02-04T08:42:24-05:00November 12th, 2014|ADT, Advanced Prostate Cancer, Bone Health, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

Outcomes Analysis of Pooled Individual Data from Randomized Clinical Trials of Degarelix versus Luteinising Hormone-Releasing Hormone Agonists

Degarelex (Firmagon) (approved by the FDA in December of 2008) is a hormonal therapy drug used to treat advanced prostate cancer that has become metastatic and castrate resistant (mCRPC). Degarelix is a GnRH receptor that binds to the pituitary GnRH receptors, reducing the release of gonadotropins leading to a quick and profound onset that blocks [...]

By Malecare|2017-10-19T10:47:44-04:00November 3rd, 2014|ADT, Advanced Prostate Cancer, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

The Well Reviewed Guide to Advanced Prostate Cancer (A Survivor Perspective) Has Been Updated and is Now Available for a free Download

Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]

By Malecare|2017-10-19T10:47:58-04:00September 30th, 2014|2nd line hormone therapy, abiraterone acetate, adjuvant therapy, ADT, Advanced Prostate Cancer, Alpha Emitting Radio Therapy, Alpharadin (radium-223), Androgan Receptor Inhibitor, Bio Chemical Recurrence, biomarkers, bisphosphonates, Bone Health, Bone Metastases, Bone Mineral Density, CAB, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Cross Resistance, Cryotherapy, CTCs, denosumab - Xgeva, Diet, Diet and Supplements, Drugs & Treatments, Early Access Program (EAP), Early/Expanded Access Programs, End-Of-Life, enzalutamide, estrogen patches, FDA, Financial, Firmagon (degarelix), General Information, genetics, HIFU, Hormone Therapy, Hot Flashes, How We Live, immunotherapy, Incontinence, inflammation, ipilimumab, ketoconazole, Medicare/Medicaid, mental health, Metastases, MRIs, NCI, neuroendocrine prostate cancer, neutropenia, Nilandron, oligometastic, On The Horizon, Our Caretakers, Pain, perineural invasion, peripheral neuropathy, Personal Experiences, prognostic tools, Prostate Ponderings, Prostvac, Provenge, PSA, PSADT, Quality of Life, radiation proctitis, radiopharmaceuticals, Radiotherapy, Research, Revlimid (lenalidomide), salvage therapy, statins, supplements, survival, survivorship, TAK700, teleconferences, Uncategorized, Understanding APC, vaccines, Vitamine D3, weight gain, Xgeva, XL184, Xofigo, Xtandi, Zometa, Zytiga|1 Comment

Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with PSA over 500 ng/ml

It is generally believed that combination hormone therapy (ADT 2, 3 or 4) is superior to mono-therapy (with just one drug). With this in mind researchers investigated the survival of hormone-naïve prostate cancer survivors diagnosed with prostate-specific antigen (PSA) over 500 ng/ml. They extracted data of prostate cancer survivors from the Japan Study Group of [...]

By Malecare|2020-02-04T12:15:51-05:00September 22nd, 2014|ADT, Advanced Prostate Cancer, Combination Therapy, Drugs & Treatments, Hormone Therapy, PSA, survival, Uncategorized, Understanding APC|2 Comments